biocon ivmp

Upload: sada-shiv

Post on 09-Apr-2018

232 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/8/2019 biocon ivmp

    1/15

  • 8/8/2019 biocon ivmp

    2/15

    Biocon is India's leadingBiocon is India's leadingbiotechnology enterprise.biotechnology enterprise.

    Biocon is India's firstBiocon is India's first

    biotechnology companybiotechnology companyestablished in Novemberestablished in November 29,29,1978.1978.

    Its headquarters is in BangaloreIts headquarters is in Bangalore

    ,India.,India.

  • 8/8/2019 biocon ivmp

    3/15

    Its CEO and MD is KiranIts CEO and MD is KiranMazumdar Shaw.Mazumdar Shaw.

    The company serves partnersThe company serves partners

    and customers in overand customers in over 5050countries. Within thecountries. Within thebiotechnology space, thebiotechnology space, thecompany rankscompany ranks 11stst in Asia inin Asia interms of revenues and marketterms of revenues and market

    capitalization andcapitalization and 1616thth

    globally.globally.

  • 8/8/2019 biocon ivmp

    4/15

    Biocon is the country's firstBiocon is the country's firstbiotechnology company tobiotechnology company toexport microbial enzymes toexport microbial enzymes toUSA and Europe.USA and Europe.

    Biocon is the firstBiocon is the first

    biotechnology company tobiotechnology company toreceive ISOreceive ISO 90019001 certificationcertificationin India.in India.

  • 8/8/2019 biocon ivmp

    5/15

    Biocon is the first company toBiocon is the first company tomanufacture insulin using amanufacture insulin using aPichia expression systemPichia expression system

    Biocon became the first IndianBiocon became the first Indianbiotech company to receive USbiotech company to receive USfunding for proprietaryfunding for proprietary

    technologies. In 1993, Biocon's R&Dtechnologies. In 1993, Biocon's R&Dand manufacturing facilitiesand manufacturing facilitiesreceived ISOreceived ISO 90019001 certification.certification.

  • 8/8/2019 biocon ivmp

    6/15

    L aunched India'sL aunched India's 11stst cancercancer

    drug BL

    OMAb EGFR.drug BL

    OMAb EGFR.

    Indias largest producer andIndias largest producer andexporter of enzymes.exporter of enzymes.

    22ndnd Indian company to crossIndian company to crossthe US $the US $ 11bn mark on the daybn mark on the dayof listing.of listing.

  • 8/8/2019 biocon ivmp

    7/15

    Products & Services

    BiopharmaceuticalsBiopharmaceuticalsEnzymesEnzymesCustom researchCustom researchClinical researchClinical research

  • 8/8/2019 biocon ivmp

    8/15

    INDIAN VALUES AND MANAGEMENT PHILOSOPHY

    Biocon's success has beenBiocon's success has beencharacterized by an enduring set ofcharacterized by an enduring set ofcorporate values based on :corporate values based on :- -InnovationInnovation

    IntegrityIntegrityStrong leadershipStrong leadershipSocial responsibilitySocial responsibility

  • 8/8/2019 biocon ivmp

    9/15

    The company mission is toThe company mission is to'Develop novel & affordable'Develop novel & affordable

    Biotherapeutics for global markets'.Biotherapeutics for global markets'.Earn as you learn. ForEarn as you learn. For 2525 yearsyearsthis unofficial philosophy hadthis unofficial philosophy hadserved Biocon well.served Biocon well.Starting out in the enzymeStarting out in the enzyme

    business inbusiness in 19781978, the Bangalore, the Bangalore- -based firm had graduallybased firm had graduallyexpanded into the pharmaceuticalexpanded into the pharmaceutical

    industry.industry.

  • 8/8/2019 biocon ivmp

    10/15

    Its recently developed capabilitiesIts recently developed capabilitiesand the political, biological,and the political, biological,intellectual, and financial benefits ofintellectual, and financial benefits ofthe Indian environment to movethe Indian environment to moveinto new areas of opportunity.into new areas of opportunity.The company applies its proprietaryThe company applies its proprietaryfermentation technologies to makefermentation technologies to make

    effective and innovative biomoleculeseffective and innovative biomoleculesin diabetology, oncology, cardiologyin diabetology, oncology, cardiologyand other therapeutic segments.and other therapeutic segments.

  • 8/8/2019 biocon ivmp

    11/15

    With its strong focus on R&DWith its strong focus on R&D

    In custom research (Syngene) in theIn custom research (Syngene) in thefields of synthetic chemistry andfields of synthetic chemistry andmolecular biology in early stagemolecular biology in early stagedrug discovery and development.drug discovery and development.

    Clinical research (Clinigene) is carriedClinical research (Clinigene) is carriedout in the fields of clinical studiesout in the fields of clinical studiesand clinical trials.and clinical trials.

  • 8/8/2019 biocon ivmp

    12/15

    The Innovation Matrix: A StrategicThe Innovation Matrix: A StrategicFrameworkFramework

    To navigate the challenges ofTo navigate the challenges of

    innovation in the next decade weinnovation in the next decade wehave adopted a wellhave adopted a well- -defineddefinedstrategic framework that willstrategic framework that will

    transform scientific discoveriestransform scientific discoveriesinto advances in human healthcareinto advances in human healthcareand generate incremental valueand generate incremental valuefor our shareholders.for our shareholders.

  • 8/8/2019 biocon ivmp

    13/15

    Biocon's integrated businessBiocon's integrated businessapproach has enabled the companyapproach has enabled the company

    to establish a significant presence into establish a significant presence inthe global biopharmaceutical marketthe global biopharmaceutical market via its product offerings and via its product offerings andcustomized, high value solutions atcustomized, high value solutions atany stage in the lifecycle of a drugany stage in the lifecycle of a drugfrom discovery to market.from discovery to market.

    Biocons vision is to be an integratedBiocons vision is to be an integratedbiopharmaceutical enterprise ofbiopharmaceutical enterprise ofglobal distinction.global distinction.

  • 8/8/2019 biocon ivmp

    14/15

    " Our ability to continuously scale" Our ability to continuously scalenew heights across thenew heights across the

    biopharmaceutical value chainbiopharmaceutical value chainenables us to realize the promise ofenables us to realize the promise offuture therapeutics. " future therapeutics. " --KiranKiran

    MazumdarMazumdar--Shaw, Chairman &Shaw, Chairman &Managing Director.Managing Director.

    Biocon is thus rapidly movingBiocon is thus rapidly movingtowards commercializing noveltowards commercializing novelbiolo ics with a " Made in India " label.biolo ics with a " Made in India " label.

  • 8/8/2019 biocon ivmp

    15/15

    As India's first and leadingAs India's first and leadingbiotechnology company Bioconbiotechnology company Biocon

    extends its support to numerousextends its support to numerouscommunity outreach and corporatecommunity outreach and corporatecitizenship initiatives with specialcitizenship initiatives with specialconcentration in the areas ofconcentration in the areas ofhealthcare, education andhealthcare, education andenvironment.environment.

    The Biocon Foundation, set up inThe Biocon Foundation, set up in20042004 has launched Arogya Rakshahas launched Arogya RakshaYojana, a unique health initiative forYojana, a unique health initiative forrural India.rural India.